Greetings and welcome to the AdaptHealth First Quarter 2021 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Chris Joyce, General Counsel. Thank you, sir. You may begin.

I would like to welcome everyone to AdaptHealth Corp.’s earnings conference call for the quarter ended March 31, 2021. Everyone should have received a copy of our earnings release earlier this morning. If not, I would like to highlight that the earnings release as well as a supplemental slide presentation regarding Q1 2021 results is posted in the Investor Relations section of our website. In a moment, we will have some prepared comments from Steve Griggs, Co-Chief Executive Officer; Josh Parnes, President; and Jason Clemens, Chief Financial Officer. We will then open the call for questions. Before we begin, I’d like to remind everyone that statements included in this conference call and in our earnings release may constitute forward-looking statements within the meaning of the private Securities Litigation Reform Act. These statements include, but are not limited to, comments regarding our financial results for 2021 and beyond. Actual results could differ materially from those projected in forward-looking statements because of a number of risk factors and uncertainties, which are discussed in our annual and quarterly SEC filings. AdaptHealth Corp. shall have no obligation to update the information provided on this call to reflect subsequent events. Additionally, on this morning’s call, we will reference certain financial measures such as EBITDA, adjusted EBITDA and adjusted EBITDA less patient equipment CapEx, which are all non-GAAP financial measures. This morning’s call is being recorded and a replay of the call will be available later today. I am now pleased to introduce our Co-Chief Executive Officer, Steve Griggs.

Thank you, Chris and thanks everyone for joining our call. Before we get to our prepared remarks, I would like to start out by thanking our 9,331 employees across the country for their unwavering resilience in the face of the ongoing pandemic and their continued commitment to serving our patients. The past 15 months have been an extraordinary time for all healthcare providers. And I couldn’t be prouder of how the AdaptHealth teams have met this challenge while remaining focused on our patients. These efforts have also been critical in helping our healthcare system partners and patients manage overwhelming healthcare demands. Additionally, our collective experience through COVID confirms that our respiratory, diabetes, sleep and home health, equipment services are crucial to meeting the overall healthcare needs of the communities we serve. Before we get to the numbers, I’d like to discuss some of the highlights of the quarter. Despite the ongoing effects of the pandemic on certain product lines, we’re very pleased with our organic growth rate of 11.5%. With the recent return of referral volumes in our sleep and hospital discharge business to pre-pandemic levels and current organic growth in diabetes and resupply, we feel confident that the balance of 2021 will meet our organic growth expectations. The integration of AdaptHealth and AeroCare organizations is proceeding quite well, as Josh will discuss in a moment. In particular, the alignment of our management teams and the speed at which we are adopting organizational best practices stand out as areas that have exceeded my expectations. We’ve made significant progress implementing each organization’s strengths across the entire organization. And as a result, we are seeing improvements in important areas of the business, such as CPAP patient compliance, which will drive meaningful revenue and cost synergies in the future. We have completed five…

Thanks, Steve. First, I’d like to echo what Steve said about our teams and how well the AdaptHealth and AeroCare workforces have combined under our new leadership team. While this is a tribute to our regional and local leaders, it also reflects the benefit of the joint integration planning efforts that started in late November 2020, supported by a team effort of the best and brightest on the AdaptHealth and AeroCare teams, we have made substantial progress rationalizing our overlapping operations and transforming many of our most important business functions. These efforts are generally meeting or exceeding our expectations and many are ready ahead of their pre-closing time lines. Specifically, we have seen great success in the areas of direct spend, branch office consolidation, re-supply operations and RCM consolidation. In the area of direct spend, we have completed our negotiations with our largest vendors and expect to see the financial benefit of these negotiations on cost of goods sold in Q2 2021 and beyond. Despite closing the transaction less than 3 months ago, our branch consolidation team, led by Shaw Rietkerk and Dan Bunting, has completed its review of our combined branches. We are well on our way to executing on a plan to rationalize our infrastructure, consolidate redundant facilities and reduce overhead. At the end of April, we have exited more than 56 overlapping branches, reducing our footprint to 614 locations, and we are continuing to evaluate further consolidation opportunities. While these two work streams have proceeded, our operations, revenue cycle management and sleep teams have been working hard to identify and implement best practices of both our companies and take advantage of synergies and technologies. While the cost and revenue synergies associated with these work streams will take some time to realize, I’m confident that the work plans…

Thanks, Josh. Good morning and thanks for joining our call. For the first quarter ending March 2021, AdaptHealth reported net revenue of $482.1 million, an increase of 152% from the first quarter of 2020. The substantial increase is a result of our company-wide focus, driving organic growth and the efficient integration of our 2020 and 2021 acquisitions, including the acquisition of AeroCare, which was completed on February 1, 2021. As a frame of reference, pro forma revenue for acquisitions was $564.1 million for the first quarter, driven primarily by AeroCare, but also from solid performance from previously announced acquisitions. As detailed in our Q1 2021 earnings supplement, our organic growth for the quarter was very strong at 11.5%, up significantly against Q4 2020 organic growth and led by new starts in our diabetes product line. There’s additional good news on the revenue front as we learned of several regulatory changes during the quarter that will provide additional tailwind to our business in 2021. Medicare sequestration relief was extended through the balance of the year. Additionally, the public health emergency was extended through mid-July, positively impacting the non-rural non-CBA DME fee schedule. Finally and importantly, the CMS published its April 2021 DME fee schedule, which resulted in higher reimbursement rates. Some of these impacts were partially accounted for in our guidance but the net incremental impact of these programs for the balance of 2021 is accounted for in our guide raise that I will discuss later. Adjusted EBITDA for the first quarter was $104.2 million, an increase of 242% from the first quarter of 2020. Our adjusted EBITDA margin of 21.6% came in as expected for the period. Adjusted EBITDA margin improved materially against the first quarter of 2020, led by turnaround results within the PCS business and higher margins from…

Thanks, Jason. Before we open the line for your questions, I’d like to address the recent announcement of Luke McGee’s unpaid leave of absence. As you know, on April 13, 2021, the company announced and had learned that Luke had been formally charged by the authorities in Denmark for alleged tax fraud related to certain private activities between 2014 and 2015. Following these revelations, the Board of Directors immediately place Luke on unpaid relief from his role as co-CEO and initiated an investigation into his contact by a special committee of independent directors. Terry Connors, the Chairman of AdaptHealth’s Audit Committee is leading the special committee, and the investigation is being conducted by DLA Piper, an independent law firm with no prior connection to the company. The primary inquiry of this investigation is to confirm that there is no connection between Luke and the alleged personal conduct and AdaptHealth’s business or operation. The investigation is well underway, and we continue to believe that Luke’s past private activities were entirely separate from the company, and the company was unaware of this alleged criminal behavior prior to April 12. As I am sure you can understand, we have been instructed by counsel that it would be inappropriate to answer any questions about this ongoing investigation. Therefore, we will not be taking any questions on this call regarding Luke’s situation or the investigation. With that, operator, please open the line for questions.

Thank you. [Operator Instructions] Our first question comes from the line of Brian Tanquilut with Jefferies. Please proceed with your question.

Hey, good morning guys. Steve, I appreciate the last comments that you made, but I guess I will ask a question kind of related to that. So, how would you address investors’ concerns about the business? Obviously, Luke was a big part of the company and he built the company together with Josh over the years and you on AeroCare. So how would you guys give comfort to investors that the company is fine, things are going well and that you guys have everything in control and that you have the bandwidth to take over some of the responsibilities that Luke had when he was CEO?

Well, we have a lot of experience in the business, like I have said I have been in it 33 years. So I am very confident that we can operate the business going forward. The vision that AeroCare had and the vision that AdaptHealth had for where this business is heading and the importance of home care evolving as a more crucial part of the healthcare delivery system, we’re very, very much aligned. That’s why the acquisition made so much sense or the combination of the companies. So we’re confident in it. I was a public company President, granted, it was in the ‘90s, but I’m pretty familiar with how capital markets work, very familiar how big markets work is evidenced by the increase in the loan and the tremendous support we got from the bank group. So I think as far as where the company is headed, I think it’s pretty clear we are going to be heading in a very same, if not similar, direction. Home care is growing tremendously. Its importance is growing. The ability to do things at home is unprecedented. You cannot take care of patients in the same manner in the future as we do today. So things have to go to the home environment, and we’re prepared for that. And we have got all these processes and people in place to take advantage of that opportunity. So we’re very, very comfortable of the ability to carry forward mission of AdaptHealth through our leadership team. We have great people in the field. We have great people in corporate offices. We are very impressed with all the processes that we’re doing. And we could go through the numbers of people that are really, really contributing to make a difference to make this a world class organization.

Hey, Brian. I will just quickly add a little color there. Obviously, Luke and I have been working closely over the last kind of 8, 9 years from when we met in 2013. We have been kind of every day hand in glove really doing some of the things in my lane, some of the things in his lane. So obviously, the vision and the execution of the vision we each kind of shared. Obviously, where we are today and where we’re set up is we feel very good about where we are, and we feel good about we are because at the end of the day, there’s a complete army behind us that’s helping getting this done every day. And like we said on the script, our employees and kind of the management team that we’ve built over the years, the additional strength that we got from both the AeroCare and now with the Spiro acquisition, really kind of HME veterans, people that know the business inside and out. But more importantly, I’m thinking about what the future of this business means in terms of technology, connected care and how this really fits into the overall healthcare delivery system, like Steve said. So we are going to definitely miss Luke’s presence now. And obviously, the strategy and where we are executing on and where this business is going is well established and we just continue to believe that we will prove that through our numbers and we continue to feel confident about executing on the plan.

I appreciate that. I guess my second question is, Josh, you mentioned the diabetes business you are happy with it. Now as I look at the sequential growth in revenue from Q1 – or from Q4 to Q1, just a little over $1 billion, right. So I know you have done some acquisitions in that side in Q1 as well. So, how are you thinking about that, right? That – shouldn’t the diabetes business have performed a little better given the deal flow in the quarter and how should we be thinking about the next quarters in terms of sequential growth?

Yes. Obviously, some of this business is a quarterly timing thing with Q4 before reset of deductibles you get a spike in December. We’re extremely proud of how the diabetes business is performing, particularly Q1, which is typically softer in that business, came ahead of our expectations for the quarter. Obviously, we haven’t been in this business all that long only since last July, but the progress we’ve been made both on e-prescribing and restructuring processes and organizing some of the acquisitions and putting them on an organic pathway to growth and kind of better bottom line numbers, we are extremely proud and confident about the current diabetes product line.

Got it. And then last question for me, I guess, Jason, as I think about the guidance, obviously, strong organic growth in Q1 raising the guidance for the year. How are you thinking about the cadence factoring in any seasonality or how should we be thinking about just the breakdown of the quarters?

Sure. I would be happy to give you some overarching comments on that. As you know, we don’t guide to the quarter, but in general, I mean, this business from a revenue perspective produces somewhere in the ballpark of 23% of annual revenue in the first quarter. It steps up from there, a touch in Q2, still under 25%. And then Q3 and 4 are bigger quarters. And as Josh said in diabetes, Q4 is particularly a big quarter. A lot of that is due to just the traditional healthcare dynamics of resetting deductibles and patient patterns, ordering patterns. And so that’s really what’s driving that. For this quarter, we are a touch under that – under that 23% I mentioned because we only had, as you know, 2 months of AeroCare as opposed to 3.

Got it. Thanks, guys.

Thank you.

Thank you. Our next question is coming from the line of Anton Hie with RBC Capital Markets. Please proceed with your question.

Thanks. Good morning, guys. Just one kind of feeds off Brian’s last question a little bit, but could you help breakdown sort of the components of the guidance raise? I think you mentioned that sequester holiday extension was already in there possibly. I’m not sure I heard that right. And then maybe how some of the latest completed M&A factors into the additional $10 million of EBITDA and then versus organic performance, so really just all those kind of three elements, how that feeds into the new guidance?

Sure, Anton. Be happy to cover that. So firstly, you have got it right on sequestration relief. In terms of other regulatory tailwinds, the CMS did publish new fee schedules on April 1. As part of that were increases around oxygen that frankly, the industry and our leadership team, has been pushing for, for a long time. I mean, once I finish, I can pass it to Steve to talk about those efforts a little bit. In terms of thinking about the size of that, I mean, you can think of the oxygen annual increase in, call it, the high single-digit millions of dollars. So of course, you only have it for 9 months, so you got to run that math. And then the rest is frankly, the Spiro acquisition that we’re just so incredibly excited about in New England. So that was the reason for the raise. I suspect we’ll talk later about synergy, but we did not change the in-year delivery or the exit rate delivery of synergy, as you saw the bands have tightened slightly. But frankly, it’s still early in the year. We are still in a pandemic and we feel great about the numbers that we put out. Steve, do you want to add a couple of comments on the oxygen increases?

Yes. The oxygen increases were related to budget neutrality condition that was put in some 15 to 20 years ago that was related to portable oxygen concentrators. When competitive bidding came in there, it seemed like that should have been come out – came out and gone away, but it didn’t. And we spent a lot of time. I was involved in it, CTRC, VGMA, home care, a bunch of people from the industry, and talking to CMS. And CMS agreed, but they just didn’t feel like they had the authority to get it out of there and discontinue it. So it had to go through legislative action. So finally, after years and years and years of industry work with the hill, they were able to take it out in April 1. So now that just level sets those rates, which resulted in that increase for everybody within the industry.

Okay, great. Obviously, a very strong organic growth performance there, but I wondered how much – or can you talk about any impact that you may have had from the severe winter storms that we saw. I know you guys have some presence in Texas and Arkansas, certainly areas that saw a lot of shutdowns, if you could just address that real quick?

Yes. I mean, certainly, the weeks of those storms, we didn’t have a lot of patient setups, but the business popped back nicely from that. And nobody is complaining about their revenues in those two states that both those states performed well over the quarter. So, they popped back nicely and had no effect really on our financial performance.

Okay. And then last one for me, are you seeing – I mean, obviously, we have kind of – seems like we are through the last real big COVID surge and the vaccines are rolling out. Are you still seeing at this point any real issues with patient access and/or kind of maybe how that trended from month-to-month within the quarter?

Yes. Generally, the healthcare businesses and the healthcare entities are open for business. So, I think that we are pretty much past the pandemic and how people are willing to come to the doctors’ offices, come to sleep labs, come to our offices to get treated whether – and still – we’re still in a lot of virtual care still. So generally speaking, that is behind us. I think everybody saw some softness in January and February. I don’t – it’s hard to figure out why that happened, but everybody kind of did that I talked to. So it was an interesting time, but March and April popped back nicely. So, we generally feel like it’s behind us. Now, I can tell you, I’ve been in this business a long time and pretty darn good about predicting the future. The whole COVID thing on oxygen is going to be interesting to see how it affects what they are calling the long-haulers and stuff like that and how it’s going to affect patients going forward, but the rest of our business should be consistently growing within our expectations.

Thanks, Steve.

Thank you.

Thank you. Our next question is coming from Mathew Blackman with Stifel. Please proceed with your question.

Good morning everyone. Thanks for taking my questions. Maybe to start, Steve a couple of questions for you and then I will have a couple of follow-ups for Jason, maybe, Steve, just in general big picture what are your priorities in 2021? Is there any particular area you’re now going to be more focused on? And in the past, you’ve talked about $100 million to $150 million in annual M&A revenue contribution. You obviously expanded the credit lines recently. Should we take that as a signal that you see opportunities that perhaps may put you above that threshold? And are there any particular areas of focus?

Well, the focus is in our core business, which is diabetes and respiratory care, which is both sleep and oxygen and ventilation. And it’s just – the activity is significant, the opportunity to get really high-quality assets, that are out there. Spiro is a good example. I’ve known Gary for a long time, and we kind of thought that he was not going to be available to merge into our company. But I think you saw the strength of the acquisition of the two companies and really got excited about joining that team, and so we’re seeing more and more of that. So I think we’re going to have a lot of opportunities in – the pipeline is robust, and it’s across the whole spectrum of that. As far as initiatives, I don’t think they have changed. I mean, when I came here and the mission was to put the organizations together, but then create that organization. I mean AdaptHealth has grown significantly through acquisition. And now it’s time to put all the pieces and parts and all the backbone and the foundation together to make this an organization that not only works today but works in the future. And we have tremendous growth opportunities and ambitions. And so we got to have to have the foundation in the organization to be able to take care of that. And that’s not just an easy task. You don’t just snap your fingers and boom, it happens. I mean the accounting, the IT, the revenue cycle management, and so we have the people in place to get all that done and to be – and if we do it right, we will actually create competitive advantage in each of those areas that we will be able to further improve it. So our focus is really on becoming a better company in all aspects of it. And we can go through our 16 or 17 different work streams that we work on every day and have people assigned to, to do that stuff to make sure that happens. And an overreaching of all that stuff is an organic sales mentality that we have to bring to this company into the combined organization that really should set us apart. And so that’s our focus. And then within it, these great assets are showing up, and we’re just not going to pass them up.

I appreciate that. And Jason, just a couple for you, I want to make sure I heard you correctly. I think you said pro forma, the first quarter sort of revenue run rate is somewhere in the $564 million range. Did I hear that correctly?

Correct.

Okay. And then G&A did spike in the quarter. Is that AeroCare related or if not, is it something else? And is that sort of the trajectory we should be thinking about from here? And that’s all for me. Thanks.

Yes, great question, Matt. G&A, I mean, there is some adjustments to EBITDA that flows through there. And even after adjusting out, we’re seeing SG&A as a percent of revenue hold pretty steady. I think that’s what you should expect from us over the next, call it, 12, 18 months, maybe a couple of bps higher as we’re continuing these investments in technology and back-office infrastructure to continue scaling. But to your point, I mean, I wouldn’t expect SG&A as a percent of revenue to really move too much over the next, call it, 12 to 18 months.

Thanks.

Thank you. Our next question is coming from Pito Chickering with Deutsche Bank. Please proceed with your question.

Good morning guys. It’s obviously been a very trying month for the management team. If you step back and think about sort of both strategy and operations, Luke was always the visionary sort of leader behind Adapt. So I’m just curious, from an acquisition perspective, will there be any changes in terms of being aggressive in M&A? And will target deals change at all over some month ago? And then, Josh, just to check on with you as well. Are there any changes that you foresee happening within the operations side of the business?

Yes. As far as acquisitions, we are on focus. I think the fact that we have $0.5 billion in available capital probably says as much as I can say about acquisitions and the ability to do that. I think the focus, again, is the same in those product lines. Home care, again, has got this huge, huge opportunity for us. And so getting as many assets out there in the field to take advantage of the future of home care is part of our mission, and we’re going to do that both through organic growth and expansion and through acquisition.

And Pito, I’ll address your second question regarding operations. So as far as we saw it, Luke and I used to joke around about, he does the easy work and we do the hard work back in where all the sausage making happens. So Luke clearly was a visionary. Luke was a great partner to work with and really helped set the organization up on solid ground in terms of where this needs to go. But again, that was also alignment of him and I getting together a number of years ago when really the team that we’ve built over the last number of years shared that vision of being able to be kind of changers or leading the change within the HME and really the post-acute care world. With regards to the operation, we have a really phenomenal team, Shaw Rietkerk, Dan Bunting from AeroCare, a lot of our kind of regional leaders state by state as we go through and even some of the folks that I’ve got to meet over the last number of months from the AeroCare team, just really the best – I’d say the best and brightest in the industry. And the other thing that I think would be changing is really just more investment in operational technology and connected care. I mean, I think we feel like, just from a footprint perspective, we’re positioned nicely, but where we can really set ourselves apart is if there is much less friction between the patient, the referral and the provider, which would be us. And again, as that gets better over time, we’re going to be able to drive kind of meaningful change in terms of velocity of amount of orders to be produced and go through our system as well as potentially, over time, become a more efficient provider and able to take some of the cost out of kind of the home care post-acute care business that we’re in. So I think you’ll see more of that from us, more investment from us in those areas. And we’re going to look to make kind of pretty aggressive moves in that scene. So more from us in the future, but we’re feeling pretty good about where the operation is today.

Okay, great. The organic growth rate, 11.5%, is the best I have seen with you guys since I’ve known you. Can you walk us through the components of that organic growth rate? How do you think that progresses throughout the year? And any color that you can give us on sort of cross-selling practices between the two companies, diabetes kind of what was the key driver of that?

Pito, how about I start on the math side and then I think pass to Steve and Josh on cross-selling and, frankly, the exciting part of the story. I mean if you look at the components of how we generally guide each of our product lines, I mean, I’ll start with the kind of the traditional somewhat slower growers, but very, very steady and consistent DME supplies to the home. I mean, we’re back above pre-pandemic levels, and we’ve reached high watermark there. And those products, we will consider to be steady as she goes for the balance of the year. As we get into respiratory frankly there is a little bit of a pop in early Q1 that we’re thinking of as nonrecurring. As Steve mentioned earlier, it’s still early to tell on the long haulers related to COVID, how that will materialize over the balance of the year. But we still feel firm about our – the range that we put out on expectations for respiratory. As you get into sleep, in terms of March, we are very happy with PAP starts and where we stand with that business. Now back to high watermark, as we said, we expected by the end of Q1 on the last call. I’ll tell you, January and February was a bit soft, but resupply has been just a tremendous story for us as we’re beating internal expectations on the resupply side. And then last, certainly not least, is diabetes. I mean, we’re just so excited about this business. Volumes are, frankly, above expectations. Growth is great. We are still somewhat cautious to raise the 10% to 12% on diabetes that we typically talk about just because we still haven’t even owned this business for a year. But everything we’re seeing is indicating that we are in the right end market for this part of the company. And as the year goes on, we will continue to refresh guidance accordingly. Regarding the cross-sell and all kind of the more exciting parts of this, I’d probably pass this to Steve and Josh.

Yes. The cross-sell is fascinating to me. So if you think about our sales reps out there in 2020, a lot of them weren’t able to get into doctors’ offices, had limited access and all this stuff. And so we still were able to produce high-quality numbers. Well, now that that’s opened up, I mean, so our reps are very, very, very busy now making sure that they get back into all of our accounts, reestablish those relationships, reestablish – bring back all the patient demographic information and the patient compliance information and patient success information to those referral sources, which they have to do. So they are incredibly busy. But even within all that, we’ve made great strides already in the cross-sell. So I was – while we’re very optimistic for it, I wasn’t expecting much because our reps were so busy. But they took it upon themselves, put in extra hours, went to the accounts and started talking about stuff. And so we’re ahead of where I really thought we’d be just because we are incredibly busy right now. But – so it’s making great progress. So we feel good about it. And I think it’s going to be a driver for us in the later part of the year as that starts building momentum and you get the doctors more comfortable sending those types of patients to the various entities.

Okay. And then two quick follow-ups here, you didn’t change your guidance around synergies for the year, I don’t think. I just wanted to ask how the integration is tracking relative to your expectations. What has gone easier and what has gone harder?

You guys want to start with operations, and I’ll follow-up on kind of what we’re seeing on the synergy dollars.

Sure. Yes, I’ll take it. This is Josh. So yes, I mean, I think like we mentioned in the script, plan has been going really well. I’d say the highlights would be kind of revenue cycle management, branch office consolidation and also the direct synergy from the purchasing, cost of goods. The stuff that takes longer is really, like Steve said, the cross-selling, some of the revenue synergies on PAP resupply. Some of the longer tail things are what we’re doing in terms of our intake and customer service and technology integrations. Those we feel very good about, but it’s definitely a longer tail and some of that will go into 2022. But otherwise, the softer stuff, which is less measured by metrics is really how well the team is getting along. The cultural aspects, no politics, really everybody just focused on getting their job done. And I think that, as a business operator all these years, that’s the thing that I feel the most confident about. Obviously, it will play out in numbers over time. But we certainly feel good about kind of where it is operationally right now, and I’ll pass it to Jason for some of the numbers.

Thanks, Josh. I’d say that, that hard work has materialized. I mean I can confirm for you that we have realized a couple of million dollars in the first quarter. And I’ll tell you that’s very heavily weighted in March. These programs have been locked in place. But depending on the contract date, the effect of day and when dollars start flowing, right, there is a shape to all of this. But the beauty of the synergy is that these are recurring dollars. So the couple of million I’m quoting will be recurring for the balance of the year. So take that number over 10 months and you can see why we are so very confident with the $30 million in-year. There is still some work to do and a big hill to climb here that we’ve got confidence in our team to do. But we’ve been cautious to increase that in-year or the exit rate synergy at this stage. But based on what we’re seeing, we’re extraordinarily confident about what we’ve got.

And just one last quick numbers question, you raised the adjusted EBITDA less CapEx by $10 million. I think you said earlier that oxygen was high single digits. So is it right to think about the guidance raise, $8 million coming from oxygen and $2 million from the Spiro transaction? Thanks so much.

Well, I’d say, Pito, it was an April 1 implementation date for oxygen. So it’s just a little bit of a ramp there. But you’re thinking of it correctly as that oxygen revenue should flow through.

Thanks guys.

Thanks, Pito.

Thank you. Our next question is coming from Richard Close with Canaccord Genuity. Please proceed with your question.

Thanks. Jason, maybe on the synergies, I just want to check in on something. In one of the answers earlier, you mentioned tightening the bands. And I just was curious what exactly that meant.

Sure. Yes. Richard, I was just talking about the guidance range on revenue, adjusted EBITDA and adjusted EBITDA less Patient Equipment CapEx. So the numbers came up, the bands tightened slightly. I think as we go over the course of the year, you’re going to see us moving those bands closer just as a course of moving through the year.

Okay. I wasn’t sure if that was related to the synergies and just wanted to check there. Moving on to acquisitions, you guys talked a lot about that over the course of the call, but I’m curious in your discussions, it’s been about a month since the news came out with respect to Luke. And I’m just curious whether – has that come up at all in any discussions with potential targets?

Well, sure, it’s come up, but I’ll just take Gary Sheehan at Spiro. Gary has known Luke for a long time. I’ve known Gary for a long time. He’s known Dan and some – Josh. And so yes, it sure came up and – but obviously, it didn’t affect the outcome of that transaction. And the other one is similar. We competed with – and AeroCare competed with Adapt in pretty much every acquisition they did. We were competing with them in every acquisition we did. We were competing – they were competing with us. So certainly, it’s going to come up, but we don’t see it affecting the ability to get a deal done.

And I’ll just add – this is Josh. I just want to give you a little more color there. So obviously, Luke always throughout the year used to tell me in working closely with him that this business is more than just about me, more than just about Luke, more than just about Josh. I think when I think about what the events of this year, the puts and the takes, if you open up middle of the night, I would say the AeroCare merger acquisition, the Spiro deal, the growth in our diabetes businesses are more than anything kind of Luke and I even on our vision would have thought would impact us positively. So in general, this business is not built around any one or multiple individuals. It’s really a team. It’s a vision. It’s infrastructure. It’s technology. It’s locations. It’s operations. It’s drivers. I mean you guys only see necessarily the face of who’s talking maybe to investors or even analysts. But obviously, there is a lot going on behind the scenes, and that’s why I think we feel confident that the machine that was built over the last number of years and the combination of a lot of good people and companies and technologies when it’s all blended into one, which is making great progress, I think, we will be very happy with the results.

And my final question is on e-prescribe. Can you just go over that again? I think you said above 30%. Where could that go over time?

Sure. So I’ll handle that. So it was 30% plus on new orders for our diabetes product line. I think we’re extremely proud of that just because we started from order number one in October. I mean, really, this is a nexus of what I mentioned a little bit in the script of we’re taking what we’ve learnt in the HME business and some of the supplies businesses and really bringing that over to our diabetes business, and our diabetes business, we’re going to be take things over to our HME business, and that’s what Steve was talking about vis-à-vis cross-selling. We have a team of 500-plus sales reps that are out in the marketplace. And as our technology continues to evolve, the ability to do product line won’t be as important in terms of differentiating how we process orders and how we deliver to our customers. So our goal, over time, is to bring all these product lines together to drive kind of a seamless experience for the patient and referring physician in their home. So I think in general, e-prescribing at 30% plus, over time – obviously, not going to be this year. But over time, we’re going to want to get that significantly over 60%, 70% plus of our business. And maybe even over time, similar to what we see in pharmacy where e-prescription is really kind of becoming much, much more dominant. Over time, we’d like to get that up north of 75% and 80%. But it will take some time to get there. But for less than 6 months, we’re extremely proud of kind of where it’s gone to, and we believe that there is room ahead. So we will continue pushing there.

Okay, thank you.

Thank you. Our next question comes from Kevin Fischbeck with Bank of America. Please proceed with your question.

Alright. Great. Still trying to reconcile the guidance raise because it sounds like the deal and the oxygen rate update are the majority of it, but then I guess, sequestration was also extended. So just trying to understand a little bit all of the pieces in there and how you think about it. And then, I guess, more importantly, how much of this guidance raise is kind of a real increase to the base as we think about flowing into 2022 and beyond that we should use as kind of the base off of which to grow. And if there is anything in here that you kind of say is one-time in nature and we should be tracking out?

Well, the sequester, I’ve spent a lot of time on the hill and with our organizations. And so we’re very, very confident that, that would be extended. When you have the hospital association and the physician association pounding CMS and, again, Congress, and we just rode off their coattails. So that was always in the numbers, the sequester numbers. And then as far as the other increase, I’ll turn it over to Jason.

Thanks, Steve. So Kevin, I guess what I’d say in terms of thinking, you’re asking about like the foundation going forward into 2022 and beyond. The way we’ve thought about sequestration, any of these supplemental programs or short-term programs is that as a management team, I mean, our job is to grow through that and above that once those programs are eliminated or stopped, and so when we talk about revenue synergy, I mean, again, we haven’t hung numbers on that, but our expectation is that we absolutely surpass any of the supplemental relief or revenue that we’re seeing in 2021. We’ve talked about PAP compliance rates. We’ve talked about PAP resupply. We’ve talked about patient pay and what we’re learning from each other, Adapt and AeroCare combined. Those will be very real numbers as we bridge into the tail end of this year and into 2022. Again, we haven’t hung specific numbers on it externally. It’s not included in guide. I would suspect over the coming quarter, we will start putting pen to paper on that for you all.

Okay. So the guide is really on the two things that need to – like that are only in the – partially in the year, the oxygen and the deals would have normalized in something bigger next year, but the guide also does include the sequestration, which we have to back out, but it did include that already. So that’s not new, right?

Correct.

That makes sense. Okay. And then, I guess, just want to follow-up on your comments about the respiratory business and the potential for long haulers. I mean are you able to or are you seeing – patients who come in with a COVID diagnosis, are you able to convert or document that they actually are turning into chronic? Love to hear any kind of color there.

Well, certainly, what we’re happy to see that a lot of these patients are getting off oxygen for their own benefit and they are going back to their normal lives. So that’s a positive for those patients. So we’re thrilled to help them with that process, having said that, there is a lot of documentation out there and a lot in the physician communities about the long-term effects that COVID had on these patients. And so you’re seeing a lot of different doctors. I mean, if you go out to National Jewish or something like that in Denver, Colorado, where there are big respiratory providers out there. They are watching these patients pretty closely, and they are more hesitant to take them off oxygen. So some of those patients that are showing those symptoms and just having trouble really get fully functional or still in oxygen. Thank gosh that a lot of them are coming off, but there is still lot to be found out of how this disease affects people long-term.

Okay, alright. Great, thanks.

Thank you. [Operator Instructions] Our next question is coming from the line of Eric Coldwell with Baird. Please proceed with your question.

Thanks very much. Sorry, I was going to ask about that sequester question, too, because based on management prior comments, we thought it was – the holiday extension was not in guidance. So I think that’s been clarified. I did want to just also clarify Spiro, the acquisition, the most recent deal, have you provided revenue for that deal and the specific EBITDA you’re looking for on an annualized basis? Again, I apologize I’ve been toggling a couple of calls here, so.

Eric, this is Jason. No problem. We have not put out specific revenue or profitability guidance on Spiro nor really on any acquisition. It’s just been our internal policy to not do that. However, in terms of the updated guide, I mean, you can run the math on our comments regarding the oxygen rates that went in place April 1. That certainly is part of the guide raise. And the other half of that – I shouldn’t say half, the other side of that raise is directly attributable to Spiro.

Got it. Thank you much. And then appreciate the comments on organic growth and the pro forma way you do that. I am curious, Jason, do you have the more traditional calculation on organic growth where a company would just take out all deals yet to annualize and look at the base business that was intact 365 days prior.

Yes. It’s a little difficult in this sector of healthcare, because as the business comes on, right? I mean – so start with the patient, right? That patient may have produced resupply revenue last year, but as they come on to our platform, right, I mean, the whole part of AdaptHealth is that we are going to resupply smarter and more efficiently to the patient of what they need when they need it. Patients will move around the system, right? I mean, so there is no real kind of like classic same-store to even compare against because we don’t operate that way. So there is a number of reasons why we don’t follow, I guess, in your words, the traditional organic growth view. What we do provide in our supplement is visibility to the prior year revenue in the quarter, regardless of ownership of the business, right? And so we’re validating that with QVs and such. So, what you are seeing year-over-year is the revenue of AdaptHealth compared against the businesses that – again, regardless of ownership year-over-year. And at 11.5%, frankly, we are feeling great. I mean, we’re feeling great about the year and the growth that’s come since Q4.

Yes. No, I get it. Thank you for that. And then I know you can’t comment on specifics of the investigation. I am curious if you have a hunch on the time line or what The Street might be looking for next in terms of updates, comments, findings? I know sometimes these things can take weeks, sometimes they take months, but I’m curious if you have a target date where you might be able to share some information with us? And then just, again, not specifics on the findings, but how do you plan to update us? Will there be a thorough discussion of everything that was reviewed or just kind of a conclusion on findings? I’m not sure if you have a process in place yet for how you’re going to share what your findings led to and kind of explain to us the level of detail that Piper and others went to in this process?

Well, your next update will be the completion of the investigation, which probably a month or so, 2 months, maybe I don’t know. We will see how fast they get through it. They want to do a thorough investigation, and I promise you they will do that, a multitude of things, but predominantly making sure that this was a private manner. We can’t comment or even guess on how it’s going to play out in Denmark. I think that would just be at best a wild gas, and so we’re not in the wild guest business. So your next update will be the investigation completion. And while we expect that to be as we’ve described, we will go through that complete and thorough process.

Sounds good. Thanks again guys. I appreciate it.

Thank you.

Sure. Thanks, Eric.

Thank you. There are no additional questions at this time. So I’d like to pass the floor back over to management for any additional closing comments.

I would just like to thank everybody, and once again, thank our 9,331 employees that every day go out there and take care of our patients, and they are doing a great job, and we continue to look forward to increased growth and increased efficiencies as we make home care a bigger part of the healthcare continuum. Thank you.

Ladies and gentlemen, this does conclude today’s teleconference. We thank you for your participation, and you may disconnect your lines at this time.